FibroGen (NASDAQ:FGEN) Receives New Coverage from Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of FibroGen (NASDAQ:FGENGet Free Report) in a note issued to investors on Sunday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

FibroGen Price Performance

NASDAQ:FGEN opened at $0.34 on Friday. The company has a market capitalization of $34.13 million, a price-to-earnings ratio of -0.14 and a beta of 0.70. The business has a 50 day moving average of $0.39 and a 200 day moving average of $0.89. FibroGen has a 1-year low of $0.30 and a 1-year high of $2.93.

FibroGen (NASDAQ:FGENGet Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.09. The business had revenue of $50.64 million during the quarter, compared to the consensus estimate of $33.00 million. During the same quarter in the previous year, the firm posted ($0.65) earnings per share. As a group, sell-side analysts anticipate that FibroGen will post -0.91 EPS for the current year.

Institutional Trading of FibroGen

Several large investors have recently modified their holdings of FGEN. Acadian Asset Management LLC boosted its holdings in FibroGen by 34.4% in the second quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock valued at $2,997,000 after acquiring an additional 860,854 shares in the last quarter. AQR Capital Management LLC increased its position in shares of FibroGen by 139.6% during the second quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock valued at $1,179,000 after buying an additional 769,586 shares during the period. XTX Topco Ltd bought a new position in FibroGen in the second quarter worth about $424,000. Cubist Systematic Strategies LLC lifted its holdings in FibroGen by 3,906.9% in the second quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock worth $256,000 after buying an additional 280,161 shares during the period. Finally, Squarepoint Ops LLC purchased a new position in shares of FibroGen during the 2nd quarter worth approximately $145,000. 72.71% of the stock is owned by institutional investors.

FibroGen Company Profile

(Get Free Report)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.

Featured Articles

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.